Oxaliplatin is a widely used chemotherapy drug for patients with advanced colorectal cancer
(CRC); however, frequent drug resistance limits its therapeutic efficacy in patients. Here, this …

Oxaliplatin resistance can develop in colorectal cancer (CRC), which may involve inhibition
of ferroptosis, although further research is needed to understand this potential mechanism …

Immune checkpoint blockade (ICB) is a promising treatment strategy for colorectal cancer
(CRC) patients. However, most CRC patients do not response well to ICB therapy …

Background Colorectal cancer (CRC), the most common cancer type, causes high morbidity
and mortality. Patients who develop drug resistance to oxaliplatin-based regimens have …

Background Currently, resistance against cisplatin (DDP) is a frequent problem for the
success of advanced gastric carcinoma (GC) chemotherapy. Here, we sought to investigate …

Abstract The BRAF V600E mutation occurs in approximately 8% of human colorectal
cancers and is associated with therapeutic resistance that is due, in part, to reactivation of …

Although many patients with colorectal cancer initially respond to the chemotherapeutic
agent oxaliplatin, acquired resistance to this treatment remains a major challenge to the long …

Drug resistance remains a major obstacle to successful cancer treatment. Genome-wide
comprehensive analysis identified a novel gene, glucocorticoid-induced protein-coding …

Ferroptosis, which is caused by iron‐dependent accumulation of lipid peroxides, is an
emerging form of regulated cell death and is considered a potential target for cancer …

Ferroptosis, implicated in several diseases, is a new form of programmed and nonapoptotic
cell death triggered by iron‐dependent lipid peroxidation after inactivation of the …